With Few Questions From FDA, Cinryze Seems Set For Smooth Committee Review

FDA will review Cinryze only for prophylaxis of hereditary angioedema at Blood Products advisory panel meeting May 2, leaving open the possibility of a split indication.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet